Interim Report January-June 2016
Unless otherwise stated in this report, all data refers to the Group. Figures in parentheses relate to the corresponding period in 2015. Positive cash flow and EBIT. Expansion of Zubsolv® to new markets and improved market access position in the US. Second quarter 2016 · Total net revenues MSEK 188.2 (126.5). · Zubsolv net revenue MSEK 178.2 (91.1). · Earnings after tax MSEK 5.0 (-84.6). · Earnings per share SEK 0.14 (-2.46). · Cash flow from operating activities MSEK 20.0 (-35.6). · Cash and cash equivalents MSEK 252.9 (282.1). · Zubsolv was selected by